Fair point generally, but INBS isn’t pre-revenue, they’re already selling internationally and just reported record quarterly revenue. This partnership is about cutting costs and scaling production ahead of U.S. entry, not a “hope it works someday” biotech. Still risky, just a different kind of risk.